The role of endothelin converting enzyme inhibition during group B Streptococcus-induced pulmonary hypertension in newborn piglets

Cristina Navarrete, Carlos Devia, Andrea C. Lessa, Dorothy Hehre, Karen Young, Octavio V. Martinez, Eduardo Bancalari, Cleide Suguihara

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

An endothelin-converting enzyme mediates the conversion from low-potency pro-endothelin to potent endothelin-1 (ET-1). Increased ET-1 levels have been observed in pulmonary hypertension of various etiologies in infants. We hypothesized that increased ET-1 levels induce pulmonary hypertension during group B Streptococcus (GBS) infusion, and this can be attenuated by the administration of an endothelin-converting enzyme inhibitor (ECEI). Twenty-two unanesthetized, chronically instrumented newborn piglets received a continuous infusion of GBS (3.5 × 108 colony-forming units/kg/min) while exposed to 100% O2. They were randomly assigned to receive a placebo (PL) or an ECEI (phosphoramidon, 30 mg/kg i.v.) 15 min after sustained pulmonary hypertension. Comparison of hemodynamic measurements and arterial blood gases at baseline and over the first 210 min from the onset of pulmonary hypertension was performed between groups. GBS infusion caused significant increases in mean pulmonary artery pressure, pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and PVR/SVR, and significant decreases in cardiac output, pH, and base excess. After the administration of ECEI, a significant reduction in pulmonary artery pressure (p < 0.0001), PVR (p < 0.001), and PVR/SVR (p < 0.01) and an improvement in cardiac output (p < 0.01) were observed during GBS infusion. The decrease in pH (p < 0.001) and base excess (p < 0.001) during GBS infusion was less marked after the administration of ECEI compared with the PL. Plasma ET-1 levels were obtained in 20 additional piglets; levels were significantly lower in the ECEI compared with PL after 3 h of GBS infusion (p < 0.02). All animals in the ECEI group survived the study period as opposed to 25% survival in the PL group (p < 0.001). These data suggest that the increased circulating ET-1 levels mediate, in part, the GBS-induced pulmonary hypertension.

Original languageEnglish
Pages (from-to)387-392
Number of pages6
JournalPediatric Research
Volume54
Issue number3
DOIs
StatePublished - Sep 1 2003

Fingerprint

Streptococcus agalactiae
Pulmonary Hypertension
Vascular Resistance
Enzyme Inhibitors
Endothelin-1
Newborn Infant
Placebos
Cardiac Output
Pulmonary Artery
Pressure
Endothelins
Endothelin-Converting Enzymes
Stem Cells
Gases
Hemodynamics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

The role of endothelin converting enzyme inhibition during group B Streptococcus-induced pulmonary hypertension in newborn piglets. / Navarrete, Cristina; Devia, Carlos; Lessa, Andrea C.; Hehre, Dorothy; Young, Karen; Martinez, Octavio V.; Bancalari, Eduardo; Suguihara, Cleide.

In: Pediatric Research, Vol. 54, No. 3, 01.09.2003, p. 387-392.

Research output: Contribution to journalArticle

@article{69c27452350a466097c1001094c0dd6f,
title = "The role of endothelin converting enzyme inhibition during group B Streptococcus-induced pulmonary hypertension in newborn piglets",
abstract = "An endothelin-converting enzyme mediates the conversion from low-potency pro-endothelin to potent endothelin-1 (ET-1). Increased ET-1 levels have been observed in pulmonary hypertension of various etiologies in infants. We hypothesized that increased ET-1 levels induce pulmonary hypertension during group B Streptococcus (GBS) infusion, and this can be attenuated by the administration of an endothelin-converting enzyme inhibitor (ECEI). Twenty-two unanesthetized, chronically instrumented newborn piglets received a continuous infusion of GBS (3.5 × 108 colony-forming units/kg/min) while exposed to 100{\%} O2. They were randomly assigned to receive a placebo (PL) or an ECEI (phosphoramidon, 30 mg/kg i.v.) 15 min after sustained pulmonary hypertension. Comparison of hemodynamic measurements and arterial blood gases at baseline and over the first 210 min from the onset of pulmonary hypertension was performed between groups. GBS infusion caused significant increases in mean pulmonary artery pressure, pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and PVR/SVR, and significant decreases in cardiac output, pH, and base excess. After the administration of ECEI, a significant reduction in pulmonary artery pressure (p < 0.0001), PVR (p < 0.001), and PVR/SVR (p < 0.01) and an improvement in cardiac output (p < 0.01) were observed during GBS infusion. The decrease in pH (p < 0.001) and base excess (p < 0.001) during GBS infusion was less marked after the administration of ECEI compared with the PL. Plasma ET-1 levels were obtained in 20 additional piglets; levels were significantly lower in the ECEI compared with PL after 3 h of GBS infusion (p < 0.02). All animals in the ECEI group survived the study period as opposed to 25{\%} survival in the PL group (p < 0.001). These data suggest that the increased circulating ET-1 levels mediate, in part, the GBS-induced pulmonary hypertension.",
author = "Cristina Navarrete and Carlos Devia and Lessa, {Andrea C.} and Dorothy Hehre and Karen Young and Martinez, {Octavio V.} and Eduardo Bancalari and Cleide Suguihara",
year = "2003",
month = "9",
day = "1",
doi = "10.1203/01.PDR.0000078272.77816.1E",
language = "English",
volume = "54",
pages = "387--392",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The role of endothelin converting enzyme inhibition during group B Streptococcus-induced pulmonary hypertension in newborn piglets

AU - Navarrete, Cristina

AU - Devia, Carlos

AU - Lessa, Andrea C.

AU - Hehre, Dorothy

AU - Young, Karen

AU - Martinez, Octavio V.

AU - Bancalari, Eduardo

AU - Suguihara, Cleide

PY - 2003/9/1

Y1 - 2003/9/1

N2 - An endothelin-converting enzyme mediates the conversion from low-potency pro-endothelin to potent endothelin-1 (ET-1). Increased ET-1 levels have been observed in pulmonary hypertension of various etiologies in infants. We hypothesized that increased ET-1 levels induce pulmonary hypertension during group B Streptococcus (GBS) infusion, and this can be attenuated by the administration of an endothelin-converting enzyme inhibitor (ECEI). Twenty-two unanesthetized, chronically instrumented newborn piglets received a continuous infusion of GBS (3.5 × 108 colony-forming units/kg/min) while exposed to 100% O2. They were randomly assigned to receive a placebo (PL) or an ECEI (phosphoramidon, 30 mg/kg i.v.) 15 min after sustained pulmonary hypertension. Comparison of hemodynamic measurements and arterial blood gases at baseline and over the first 210 min from the onset of pulmonary hypertension was performed between groups. GBS infusion caused significant increases in mean pulmonary artery pressure, pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and PVR/SVR, and significant decreases in cardiac output, pH, and base excess. After the administration of ECEI, a significant reduction in pulmonary artery pressure (p < 0.0001), PVR (p < 0.001), and PVR/SVR (p < 0.01) and an improvement in cardiac output (p < 0.01) were observed during GBS infusion. The decrease in pH (p < 0.001) and base excess (p < 0.001) during GBS infusion was less marked after the administration of ECEI compared with the PL. Plasma ET-1 levels were obtained in 20 additional piglets; levels were significantly lower in the ECEI compared with PL after 3 h of GBS infusion (p < 0.02). All animals in the ECEI group survived the study period as opposed to 25% survival in the PL group (p < 0.001). These data suggest that the increased circulating ET-1 levels mediate, in part, the GBS-induced pulmonary hypertension.

AB - An endothelin-converting enzyme mediates the conversion from low-potency pro-endothelin to potent endothelin-1 (ET-1). Increased ET-1 levels have been observed in pulmonary hypertension of various etiologies in infants. We hypothesized that increased ET-1 levels induce pulmonary hypertension during group B Streptococcus (GBS) infusion, and this can be attenuated by the administration of an endothelin-converting enzyme inhibitor (ECEI). Twenty-two unanesthetized, chronically instrumented newborn piglets received a continuous infusion of GBS (3.5 × 108 colony-forming units/kg/min) while exposed to 100% O2. They were randomly assigned to receive a placebo (PL) or an ECEI (phosphoramidon, 30 mg/kg i.v.) 15 min after sustained pulmonary hypertension. Comparison of hemodynamic measurements and arterial blood gases at baseline and over the first 210 min from the onset of pulmonary hypertension was performed between groups. GBS infusion caused significant increases in mean pulmonary artery pressure, pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and PVR/SVR, and significant decreases in cardiac output, pH, and base excess. After the administration of ECEI, a significant reduction in pulmonary artery pressure (p < 0.0001), PVR (p < 0.001), and PVR/SVR (p < 0.01) and an improvement in cardiac output (p < 0.01) were observed during GBS infusion. The decrease in pH (p < 0.001) and base excess (p < 0.001) during GBS infusion was less marked after the administration of ECEI compared with the PL. Plasma ET-1 levels were obtained in 20 additional piglets; levels were significantly lower in the ECEI compared with PL after 3 h of GBS infusion (p < 0.02). All animals in the ECEI group survived the study period as opposed to 25% survival in the PL group (p < 0.001). These data suggest that the increased circulating ET-1 levels mediate, in part, the GBS-induced pulmonary hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0041968432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041968432&partnerID=8YFLogxK

U2 - 10.1203/01.PDR.0000078272.77816.1E

DO - 10.1203/01.PDR.0000078272.77816.1E

M3 - Article

C2 - 12788984

AN - SCOPUS:0041968432

VL - 54

SP - 387

EP - 392

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 3

ER -